“CAR T has the potential to become one of the most powerful anti-cancer agents for hematologic cancers,” he said. Our similar cultures and histories of driving rapid innovation in order to bring more effective and safer products to as many patients as possible make this an excellent strategic fit.”Īrie Belldegrun, chairman, president and CEO of Kite Pharma, said the company is “excited that Gilead, one of the most innovative companies in the industry, recognized this value and shares our passion for developing cutting-edge and potentially curative therapies for patients.” “We are greatly impressed with the Kite team and what they have accomplished, and share their belief that cell therapy will be the cornerstone of treating cancer. “The field of cell therapy has advanced very quickly, to the point where the science and technology have opened a clear path toward a potential cure for patients,” he said. “The acquisition of Kite establishes Gilead as a leader in cellular therapy and provides a foundation from which to drive continued innovation for people with advanced cancers,” Gilead President and CEO John Milligan said in a statement. The FDA is reviewing the company’s axicabtagene ciloleucel, or axi-cel, therapy for the treatment of refractory aggressive non-Hodgkin lymphoma.
0 kommentar(er)
